|
1
|
Neal RD, Sun F, Emery JD and Callister ME:
Lung cancer. BMJ. 365:l17252019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of nonsnon-small cell lung cancer.
Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M and Rabe KF: Precision diagnosis
and treatment for advanced non-small-cell lung cancer. N Engl J
Med. 377:849–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tandberg DJ, Tong BC, Ackerson BG and
Kelsey CR: Surgery versus stereotactic body radiation therapy for
stage I non-small cell lung cancer: A comprehensive review. Cancer.
124:667–678. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu SG and Shih JY: Management of acquired
resistance to EGFR TKI-targeted therapy in advanced non-small cell
lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu WJ, Du Y, Wen R, Yang M and Xu J: Drug
resistance to targeted therapeutic strategies in non-small cell
lung cancer. Pharmacol Ther. 206:1074382020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dai D, Wang H, Zhu L, Jin H and Wang X:
N6-methyladenosine links RNA metabolism to cancer progression. Cell
Death Dis. 9:1242018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maity A and Das B: N6-methyladenosine
modification in mRNA: Machinery, function and implications for
health and diseases. FEBS J. 283:1607–1630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He L, Li H, Wu A, Peng Y, Shu G and Yin G:
Functions of N6-methyladenosine and its role in cancer. Mol Cancer.
18:1762019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR
and Qian SB: Dynamic m(6)A mRNA methylation directs translational
control of heat shock response. Nature. 526:591–594. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang
L, Jia G, Yu M, Lu Z, Deng X, et al: A METTL3-METTL14 complex
mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem
Biol. 10:93–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ping XL, Sun BF, Wang L, Xiao W, Yang X,
Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, et al: Mammalian WTAP is
a regulatory subunit of the RNA N6-methyladenosine
methyltransferase. Cell Res. 24:177–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roundtree IA, Evans ME, Pan T and He C:
Dynamic RNA modifications in gene expression regulation. Cell.
169:1187–1200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun T, Wu R and Ming L: The role of m6A
RNA methylation in cancer. Biomed Pharmacother. 112:1086132019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin S, Choe J, Du P, Triboulet R and
Gregory RI: The m(6)A Methyltransferase METTL3 promotes translation
in human cancer cells. Mol Cell. 62:335–345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng W, Li J, Chen R, Gu Q, Yang P, Qian
W, Ji D, Wang Q, Zhang Z, Tang J and Sun Y: Upregulated METTL3
promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK
signaling pathway. J Exp Clin Cancer Res. 38:3932019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Q, Chen C, Ding Q, Zhao Y, Wang Z,
Chen J, Jiang Z, Zhang Y, Xu G, Zhang J, et al: METTL3-mediated
m6A modification of HDGF mRNA promotes gastric cancer
progression and has prognostic significance. Gut. 69:1193–1205.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen M, Wei L, Law CT, Tsang FH, Shen J,
Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al: RNA
N6-methyladenosine methyltransferase-like 3 promotes liver cancer
progression through YTHDF2-dependent posttranscriptional silencing
of SOCS2. Hepatology. 67:2254–2270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tao Z, Zhao Y and Chen X: Role of
methyltransferase-like enzyme 3 and methyltransferase-like enzyme
14 in urological cancers. PeerJ. 8:e95892020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to the 2015 world health
organization classification of tumors of the lung, pleura, thymus
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ni WJ and Leng XM: Down-regulated miR-495
can target programmed cell death 10 in ankylosing spondylitis. Mol
Med. 26:502020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang S, Zhao BS, Zhou A, Lin K, Zheng S,
Lu Z, Chen Y, Sulman EP, Xie K, Bögler O, et al: m6A
Demethylase ALKBH5 maintains tumorigenicity of glioblastoma
stem-like cells by sustaining FOXM1 expression and cell
proliferation program. Cancer Cell. 31:591–606.e6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dominissini D, Moshitch-Moshkovitz S,
Salmon-Divon M, Amariglio N and Rechavi G: Transcriptome-wide
mapping of N(6)-methyladenosine by m(6)A-seq based on
immunocapturing and massively parallel sequencing. Nat Protoc.
8:176–189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zaccara S, Ries RJ and Jaffrey SR:
Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell
Biol. 20:608–624. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun
L, Wang Y, Li X, Xiong XF, Wei B, et al: RNA N6-methyladenosine
demethylase FTO promotes breast tumor progression through
inhibiting BNIP3. Mol Cancer. 18:462019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang H, Xu B and Shi J: N6-methyladenosine
METTL3 promotes the breast cancer progression via targeting Bcl-2.
Gene. 22:1440762020. View Article : Google Scholar
|
|
28
|
Zhang H, Shi X, Huang T, Zhao X, Chen W,
Gu N and Zhang R: Dynamic landscape and evolution of m6A
methylation in human. Nucleic Acids Res. 48:6251–6264. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang Z, Kidwell RL, Deng H and Xie Q:
Epigenetic N6-methyladenosine modification of RNA and DNA regulates
cancer. Cancer Biol Med. 17:9–19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang C, Samanta D, Lu H, Bullen JW, Zhang
H, Chen I, He X and Semenza GL: Hypoxia induces the breast cancer
stem cell phenotype by HIF-dependent and ALKBH5-mediated
m6A-demethylation of NANOG mRNA. Proc Natl Acad Sci USA.
113:E2047–E2056. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu ZX, Li LM, Sun HL and Liu SM: Link
Between m6A modification and cancers. Front Bioeng Biotechnol.
6:892018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zeng C, Huang W, Li Y and Weng H: Roles of
METTL3 in cancer: Mechanisms and therapeutic targeting. J Hematol
Oncol. 13:1172020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang
Z, Liu Y, Zhang X, Zhang W and Ye L: HBXIP-elevated
methyltransferase METTL3 promotes the progression of breast cancer
via inhibiting tumor suppressor let-7g. Cancer Lett. 415:11–19.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin Y, Wei X, Jian Z and Zhang X: METTL3
expression is associated with glycolysis metabolism and sensitivity
to glycolytic stress in hepatocellular carcinoma. Cancer Med.
9:2859–2867. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang H, Deng Q, Lv Z, Ling Y, Hou X, Chen
Z, Dinglin X, Ma S, Li D, Wu Y, et al: N6-methyladenosine induced
miR-143-3p promotes the brain metastasis of lung cancer via
regulation of VASH1. Mol Cancer. 18:1812019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jin H, Ying X, Que B, Wang X, Chao Y,
Zhang H, Yuan Z, Qi D, Lin S, Min W, et al:
N6-methyladenosine modification of ITGA6 mRNA promotes
the development and progression of bladder cancer. EBioMedicine.
47:195–207. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH,
Wang F, Wang TT, Xu QG, Zhou WP and Sun SH: METTL14 suppresses the
metastatic potential of hepatocellular carcinoma by modulating
N6-methyladenosine-dependent primary MicroRNA
processing. Hepatology. 65:529–543. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu X, Qin J, Gao T, Li C, Chen X, Zeng K,
Xu M, He B, Pan B, Xu X, et al: Analysis of METTL3 and METTL14 in
hepatocellular carcinoma. Aging (Albany NY). 12:21638–21659. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wanna-Udom S, Terashima M, Lyu H, Ishimura
A, Takino T, Sakari M, Tsukahara T and Suzuki T: The m6A
methyltransferase METTL3 contributes to Transforming Growth
Factor-beta-induced epithelial-mesenchymal transition of lung
cancer cells through the regulation of JUNB. Biochem Biophys Res
Commun. 524:150–155. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang X, Lv D, Yang X, Li M and Zhang H:
m6A RNA methylation regulators could contribute to the occurrence
of chronic obstructive pulmonary disease. J Cell Mol Med.
24:12706–12715. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H,
Wu M, Liang Y, Zhu F, Zhang Y, Zhang X, et al: The m6A
methyltransferase METTL3 promotes bladder cancer progression via
AFF4/NF-κB/MYC signaling network. Oncogene. 38:3667–3680. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang Z and Jiang X, Li D and Jiang X:
HBXIP promotes gastric cancer via METTL3-mediated MYC mRNA m6A
modification. Aging (Albany NY). 12:24967–24982. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xiang S, Liang X, Yin S, Liu J and Xiang
Z: N6-methyladenosine methyltransferase METTL3 promotes colorectal
cancer cell proliferation through enhancing MYC expression. Am J
Transl Res. 12:1789–1806. 2020.PubMed/NCBI
|
|
44
|
Chui K and Zhang Z: Bcl-2 overexpression
inhibits generation of intracellular reactive oxygen species and
blocks adriamycin-induced apoptosis in bladder cancer cells. Asian
Pac J Cancer Prev. 14:895–901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu G and Tang X: Troxerutin (TXN)
potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer
through suppressing STAT3/NF-κB and Bcl-2 signaling pathways.
Biomed Pharmacother. 92:95–107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim R, Emi M, Tanabe K and Toge T:
Therapeutic potential of antisense Bcl-2 as a chemosensitizer for
cancer therapy. Cancer. 101:2491–502. 2004. View Article : Google Scholar : PubMed/NCBI
|
